Zobrazeno 1 - 10
of 81
pro vyhledávání: ''
Autor:
Michael Bonelli, Stephan Blüml, Philipp Hofer, Leonhard X. Heinz, Stefan Winkler, Daniela Sieghart, Josef S Smolen, Marianne Graninger, Daniel Aletaha, Karin Stiasny, Helmuth Haslacher, Helga Radner, Selma Tobudic, Maximilian Koblischke, Renate Thalhammer, Thomas Perkmann, Daniel Mrak, Judith H. Aberle
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesEvidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a humoral and T-cell-mediated immune response against SARS-C
Autor:
María Laura Acosta Felquer, Luciano LoGiudice, Enrique R. Soriano, María Laura Galimberti, Luis Daniel Mazzuoccolo, Javier Rosa
Publikováno v:
Annals of the Rheumatic Diseases. 81:74-79
ObjectivesTo compare the incidence of psoriatic arthritis (PsA) in patients with psoriasis (PsO) according to different treatments for their skin: topics/no treatment, conventional disease-modifying antirheumatic drugs (DMARDs) (cDMARDs) or biologica
Autor:
Gerd Sutter, Lukas Graalmann, Michael Hallensleben, Lea A. I. Vaas, Ulrich Kalinke, Murielle Verboom, Reinhold E. Schmidt, Torsten Witte, Mario Köster, Carlos A. Guzmán, Himanshu Manchanda, Matthias Bruhn, Katharina Borst, Theresa Graalmann
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases
England
Annals of the rheumatic diseases
England
ObjectivesThe monoclonal anti-CD20 antibody rituximab is frequently applied in the treatment of lymphoma as well as autoimmune diseases and confers efficient depletion of recirculating B cells. Correspondingly, B cell-depleted patients barely mount d
Autor:
Antonio Manzo, Silvia Balduzzi, Eleonora Mauric, Laura Bogliolo, Fausto Baldanti, Terenzj Luvaro, Bernardo D’onofrio, Daniele Lilleri, Serena Bugatti, Maria Immacolata Greco, Ludovico De Stefano, Michele di Lernia, Irene Cassaniti, Iolanda Mazzucchelli, Carlomaurizio Montecucco
Publikováno v:
Annals of the Rheumatic Diseases. 80:1635-1638
Strategies aimed at expediting immunisation campaigns against COVID-19 include providing single vaccine doses to individuals with previous exposure to SARS-CoV-2 and delaying second doses. While such approaches are effective at the population level,
Autor:
Tena K. Li, Cheuk-Wan Yim, Junbin Huang, Lai-Shan Tam, Tommy Tsz-On Lam, Vincent Lo, James F. Griffith, Ho So, Isaac T Cheng, Jolie Lee, Kitty Y Kwok, Lin Shi, Vivian Wing-Yin Hung, Vivian W Y Lee, Sze-Lok Lau, Jack Lee, Ling Qin, Edmund K. Li, Evelyn Chow
Publikováno v:
Annals of the Rheumatic Diseases. 80:981-988
ObjectiveTo evaluate the effects of denosumab on erosion healing at 2–4 metacarpophalangeal (MCP) head as determined by high-resolution peripheral quantitative CT (HR-pQCT) in patients with rheumatoid arthritis (RA) with stable disease.MethodsThis
Autor:
Nirupam Purkayastha, Myles Lewis, Katriona Goldmann, W.S. Tan, Alessandra Nerviani, Stephen Kelly, Marie-Astrid Boutet, Tamás Lajtos, Costantino Pitzalis, Rebecca Hands
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTo determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and explore mechanistic links between diseased tissue pathology and clinical outcomes.Methods
Autor:
Hendrik Schulze-Koops, Andrea Shapiro, Dimitrios A. Pappas, Kevin L. Winthrop, Harry Shi, David Gold, D. Henrohn, Gustavo Citera, Alina Onofrei, Carol A. Connell
Publikováno v:
Annals of the Rheumatic Diseases
A randomised, open-label, blinded endpoint post-authorisation safety study (Study A3921133; NCT02092467; database not locked and subject to change) evaluated the safety of tofacitinib 5 mg and 10 mg twice daily (BID) versus tumour necrosis factor inh
Publikováno v:
Annals of the rheumatic diseases. 80(10)
There is a paucity of data on the effect of antirheumatic drugs on serological responses to COVID-19 vaccines. Anti-CD20 therapies deplete B-cells, with reconstitution often not beginning for 6–9 months after infusion, resulting in diminished humor
Publikováno v:
Annals of the rheumatic diseases. 80(11)
The advent of biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) has improved the management of rheumatoid arthritis (RA) dramatically. However, there are patients who have not been controlled adequately, and EULAR
Autor:
Monika Hansson, Paul P. Tak, Matthijs Janssen, M. Starmans-Kool, Niek de Vries, Aeilko H. Zwinderman, Man Wai Tang, M Safy, KI Maijer, Danielle M. Gerlag, Sander W. Tas, Maria J. H. de Hair, Astrid van Tubergen
Publikováno v:
Annals of the Rheumatic Diseases, 78(2), 179-185. BMJ Publishing Group
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 78(2), 179-185. BMJ Publishing Group
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 78(2), 179-185. BMJ Publishing Group
ObjectivesWe explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis develo